Ora treatment for gastric cancer: new choices, better choices?

被引：58

作者：

Cascinu, Stefanu ^{[1
]}

机构：

[1] Univ Politecn Marche, Ancona Univ Hosp, Dept Med Oncol, Ancona, Italy

来源：

LANCET ONCOLOGY | 2008年 / 9卷 / 03期

关键词：

D O I：

10.1016/S1470-2045(08)70042-1

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页码：188 / 189

页数：2

共 12 条

[1]

BOKU N, 2007, J CLIN ONCOL, V25, pS965, DOI DOI 10.1200/JCO.2006.10.0131

[2] Capecitabine and oxaliplatin for advanced esophagogastric cancer [J].

Cunningham, David ;

Starling, Naureen ;

Rao, Sheela ;

Iveson, Timothy ;

Nicolson, Marianne ;

Coxon, Fareeda ;

Middleton, Gary ;

Daniel, Francis ;

Oates, Jacqueline ;

Norman, Andrew Richard .

NEW ENGLAND JOURNAL OF MEDICINE, 2008, 358 (01) :36-46

[3]

Dank M, 2005, J CLIN ONCOL, V23, p308S

[4]

Kang Y, 2007, J CLIN ONCOL, V25

[5]

Kang Y, 2006, J CLIN ONCOL, V24, p183S

[6] S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): a phase III trial [J].

Koizumi, Wasaburo ;

Narahara, Hiroyuki ;

Hara, Takuo ;

Takagane, Akinori ;

Akiya, Toshikazu ;

Takagi, Masakazu ;

Miyashita, Kosei ;

Nishizaki, Takashi ;

Kobayashi, Osamu ;

Takiyama, Wataru ;

Toh, Yasushi ;

Nagaie, Takashi ;

Takagi, Seiichi ;

Yamamura, Yoshitaka ;

Yanaoka, Kimihiko ;

Orita, Hiroyuki ;

Takeuchi, Masahiro .

LANCET ONCOLOGY, 2008, 9 (03) :215-221

[7] Extended safety and efficacy data on S-1 plus cisplatin in patients with untreated, advanced gastric carcinoma in a multicenter phase II study [J].

Lenz, Heinz-Joseph ;

Lee, Fa-Chyi ;

Haller, Daniel G. ;

Singh, Deepti ;

Benson, A. B., III ;

Strumberg, Dirk ;

Yanagihara, Ronald ;

Yao, James C. ;

Phan, Alexandra T. ;

Ajani, Jaffer A. .

CANCER, 2007, 109 (01) :33-40

[8] Phase II study of oxaliplatin, fluorouracil, and folinic acid in locally advanced or metastatic gastric cancer patients [J].

Louvet, C ;

André, T ;

Tigaud, JM ;

Gamelin, E ;

Douillard, JY ;

Brunet, R ;

François, E ;

Jacob, JH ;

Levoir, D ;

Taamma, A ;

Rougier, P ;

Cvitkovic, E ;

de Gramont, A .

JOURNAL OF CLINICAL ONCOLOGY, 2002, 20 (23) :4543-4548

[9] Prospective randomized trial comparing mitomycin, cisplatin, and protracted venous-infusion fluorouracil (PV1 5-FU) with epirubicin, cisplatin, and PV15-FU in advanced esophagogastric cancer [J].

Ross, P ;

Nicolson, M ;

Cunningham, D ;

Valle, J ;

Seymour, M ;

Harper, P ;

Price, T ;

Anderson, H ;

Iveson, T ;

Hickish, T ;

Lofts, F ;

Norman, A .

JOURNAL OF CLINICAL ONCOLOGY, 2002, 20 (08) :1996-2004

[10] Development of a novel form of an oral 5-fluorouracil derivative (S-1) directed to the potentiation of the tumor selective cytotoxicity of 5-fluorouracil by two biochemical modulators [J].

Shirasaka, T ;

Shimamato, Y ;

Ohshimo, H ;

Yamaguchi, M ;

Kato, T ;

Yonekura, K ;

Fukushima, M .

ANTI-CANCER DRUGS, 1996, 7 (05) :548-557

← 1 2 →